ESR1 and breast cancer: Finally, we also performed the same experiment in a cell line modeling a luminal metastatic BC resistant to the ET drugs because they express an ERα missense mutation (i.e., Y537S) that renders the receptor hyperactive and sustains uncontrolled cell proliferation28,29.